Submit a preprint

Title *

Evolution of HIV virulence in response to widespread scale up of antiretroviral therapy: a modeling studyuse asterix (*) to get italics

Authors *

Herbeck JT, Mittler JE, Gottlieb GS, Goodreau SM, Murphy JT, Cori A, Pickles M, Fraser CPlease use the format "First name initials family name" as in "Marie S. Curie, Niels H. D. Bohr, Albert Einstein, John R. R. Tolkien, Donna T. Strickland"

Year *

2016

Picture *

Abstract *

<p>There are global increases in the use of HIV antiretroviral therapy (ART), guided by clinical benefits of early ART initiation and the efficacy of treatment as prevention of transmission. Separately, it has been shown theoretically and empirically that HIV virulence can evolve over time; observed virulence levels may reflect an adaptive balance between infected lifespan and per-contact transmission rate. However, the potential effects of widespread ART usage on HIV virulence are unknown. To predict these effects, we used an agent-based stochastic model to simulate evolutionary trends in HIV virulence, using set point viral load as a proxy for virulence. We calibrated our model to prevalence and incidence trends of South Africa. We explored two distinct ART scenarios: (1) ART initiation based on HIV-infected individuals reaching a CD4 count threshold; and (2) ART initiation based on individual time elapsed since HIV infection (a scenario that mimics “universal testing and treatment” (UTT) aspirations). In each case, we considered a range in population uptake of ART. We found that HIV virulence is generally unchanged in scenarios of CD4-based initiation. However, with ART initiation based on time since infection, virulence can increase moderately within several years of ART rollout, under high coverage levels and early treatment initiation (albeit within the context of epidemics that are rapidly decreasing in size). Sensitivity analyses suggested the impact of ART on virulence is relatively insensitive to model calibration. Our modeling study suggests that increasing HIV virulence driven by UTT is likely not a major public health concern, but should be monitored in sentinel surveillance, in a manner similar to transmitted resistance to antiretroviral drugs.</p>

Indicate the full web address (DOI or URL) giving public access to these data (if you have any problems with the deposit of your data, please contact contact@evolbiol.peercommunityin.org). In case all raw data are included in the preprint, indicate the DOI or URL of the preprint. *

You should fill this box only if you chose 'All or part of the results presented in this preprint are based on data'. URL must start with http:// or https://

Indicate the full web address (DOI or URL) giving public access to these scripts (if you have any problems with the deposit of your scripts, please contact contact@evolbiol.peercommunityin.org). In case all raw scripts are included in the preprint, indicate the DOI or URL of the preprint. *

You should fill this box only if you chose 'Scripts were used to obtain or analyze the results'. URL must start with http:// or https://

Indicate the full web address (DOI, SWHID or URL) giving public access to these codes (if you have any problems with the deposit of your codes, please contact contact@evolbiol.peercommunityin.org). In case all raw codes are included in the preprint, indicate the DOI or URL of the preprint. *

You should fill this box only if you chose 'Codes have been used in this study'. URL must start with http:// or https://

Keywords (optional)

virus, HIV, virulence, treatment

Methods that require specific expertise (optional)

NonePlease indicate the methods that may require specialised expertise during the peer review process (use a comma to separate various required expertises).

Thematic fields *

Bioinformatics & Computational Biology, Evolutionary Applications, Evolutionary Epidemiology

Suggested reviewers - Suggest up to 10 reviewers (provide names and Email addresses). (Optional)

e.g. John Doe john@doe.com

No need for them to be recommenders of PCIEvolBiol. Please do not suggest reviewers for whom there might be a conflict of interest. Reviewers are not allowed to review preprints written by close colleagues (with whom they have published in the last four years, with whom they have received joint funding in the last four years, or with whom they are currently writing a manuscript, or submitting a grant proposal), or by family members, friends, or anyone for whom bias might affect the nature of the review - see the code of conduct

Opposed reviewers - Suggest up to 5 people not to invite as reviewers. (Optional)

e.g. John Doe john@doe.com

Submission date

2016-12-16 20:54:08

Recommender

Samuel Alizon

Reviewers

or Register
Submit a preprint

MANAGING BOARD

Guillaume Achaz
Juan Arroyo
Trine Bilde
Dustin Brisson
Marianne Elias
Inês Fragata
Matteo Fumagalli
Tatiana Giraud
Frédéric Guillaume
Ruth Hufbauer
Sara Magalhaes
Caroline Nieberding
Michael David Pirie
Tanja Pyhäjärvi

Fernando Racimo
Tanja Schwander
Alejandro Gonzalez Voyer

RECOMMENDERS

MANAGING BOARD

MEMBER OF

INDEXED BY